Posted by AGORACOM-JC
at 4:18 PM on Thursday, April 15th, 2021
If you think about balloons / blimps when thinking about Helium uses, we wouldn’t blame you … but you’d also be missing out on a much much bigger picture.
Looking beyond just balloons, Helium is a high tech gas, with many uses in rocket engines, semiconductors, electronics, and health care. These sectors pressure the demand for helium in concert, making it a gas in very short supply, causing the price to rise.
Saskatchewan is one of the only places on earth with current and past production of primary Helium. This is where Royal Helium comes into play as they are one of the largest land holders searching for Helium and recently announced that testing identified zones that range in thickness from five meters to in excess of 30 meters. These zones returned levels ranging from 0.33% to 0.94%, demonstrating the commercial potential of the Climax project
Worldwide usable Helium is in short supply as demand is increasing, making it a high-priced commodity, take a seat and discover why Royal Helium is the next SmallCap Stock to discover.
Posted by AGORACOM-JC
at 9:17 AM on Thursday, April 15th, 2021
joined Faire, an online wholesale retail marketplace. Fast Magazine names Faire among “The 10 most innovative retail companies of 2020”.
Fast Magazine names Faire among “The 10 most innovative retail companies of 2020
Faire allows PK Beans to expand their omni-channel business model and have greater exposure and access to 150,000 retailers across North America.
Vancouver, British Columbia–(April 15, 2021) – Peekaboo Beans Inc.https://agoracom.com/ir/PKBeans (CSE: BEAN) (OTC Pink: PBBSF) (“PK Beans” or the “Company”) is pleased to share that they have joined Faire, an online wholesale retail marketplace. Fast Magazine names Faire among “The 10 most innovative retail companies of 2020”.
Faire allows PK Beans to expand their omni-channel business model and have greater exposure and access to 150,000 retailers across North America. Faire marketplace allows for PK Beans to continue to support and maintain all current wholesale relationships, while being able to offer these customers the net terms provided by Faire; providing customers greater breathing room and more incentive to purchase PK Beans; during an otherwise difficult time in retail due to the ever growing and changing impacts of the COVID-19 Pandemic.
“We are excited reach new retailers and support more grassroots retail brands in communities across North America. Faire makes it easy and accessible to reach these business to business customers, and this adds another arm to our omni channel sales model,” states Traci Costa, PK Beans CEO and Founder.
PK Beans also wishes to announce the closing of its previously disclosed private placement of convertible debenture units for total gross proceeds of $110,000 (the “Offering“). The Company raised $110,000 through the issuance of 110 convertible debenture units at a price of $1,000 per convertible debenture unit. Each convertible debenture unit was comprised of one unsecured convertible debenture with a principal amount of $1,000 each and 5,000 common share purchase warrants. Each warrant entitles the holder thereof to acquire on common share of the Company at a price of $0.15 per share until April 9, 2023. The debentures will mature and be repayable on April 9, 2023 and bear interest at a rate of 12% per annum until maturity.
The net proceeds of the Offering will be used for general working capital purposes. The terms of the Offering are further described in the Company’s news release dated April 8, 2021.
All securities issued in connection with the Offering are subject to a statutory hold period expiring on August 10, 2021 in accordance with applicable securities legislation.
Posted by AGORACOM-JC
at 8:16 AM on Thursday, April 15th, 2021
Company Stock Is Now More Accessible to U.S. Investors
United States investors may now more easily trade Empower’s OTC stock (OTC PINK:EPWCF) in addition to Empower’s listing on the CSE (CSE:CBDT) and (FRA:8EC).
VANCOUVER B.C. / April 15, 2021 /EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTC PINK:EPWCF) (“Empower” or the “Company”) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – is pleased to announce it is now eligible for Depository Trust Company (“DTC”) services in relation to Empower’s listing on the OTC.
United States investors may now more easily trade Empower’s OTC stock (OTC PINK:EPWCF) in addition to Empower’s listing on the CSE (CSE:CBDT) and (FRA:8EC).
“Convenience is a core part of Empower’s overall strategy for our approach to integrated healthcare, so our capital markets strategy should be the same. I’m thrilled that trading Empower’s shares will now be easier for existing and potential shareholders in the U.S.,” said Steven McAuley, Chairman & CEO of Empower. “Empower has a strong and growing presence in the United States market operationally as well as for investors. We’re confident that we will see enhanced trading liquidity as a result of our DTC eligibility.”
DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world’s largest securities depositories that manages the electronic clearing and settlement of publicly traded companies. Empower is now eligible to be electronically cleared and settled through the DTC and is therefore considered “DTC eligible”. This electronic method of clearing securities streamlines the process of trading, enhances liquidity, and provides direct access to investors and brokers in the U.S. OTC capital markets.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
Posted by AGORACOM-JC
at 8:12 AM on Thursday, April 15th, 2021
Shipments have commenced across Canada
National sales coverage in full deployment through a dedicated key account managers team
Private and public reimbursement activities on target.
MONTREAL , April 15, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has commenced commercial shipments across Canada of Redesca™ and Redesca HP™, its low molecular weight heparin (“LMWH”) biosimilar.
“Making Redesca™ widely available in Canada is a key element of our commercialization plans and we are pleased to have done so ahead of target. We continue to work on expanding both public and private reimbursement coverage across all provinces”, said Steve Saviuk , Valeo’s Chief Executive Officer. ” Redesca™ is the first of three transformative products that Valeo is launching this year and it will be accretive to second quarter revenues with increasing sales growth in the quarters to come.”
Commenting on the Redesca™ commercial launch, Frederic Fasano , Valeo’s President and Chief Operating Officer said; “Redesca™ is now available for patients, both at retail pharmacies and hospitals. The combination of a strong and proven safety profile, a complete product line, a robust supply chain on top of material savings to payers, contributes to the compelling Redesca™ value proposition for patients, clinicians and healthcare systems. We look forward to realizing Redesca™’s full potential over the coming quarters”.
In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against COVID-19. The World Health Organization’s (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.
About Redesca®, Redesca HP®
Redesca® is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca® has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Posted by AGORACOM-JC
at 9:28 AM on Wednesday, April 14th, 2021
Announced that it has appointed Rick Bowes, CD, MA, MBA in the new position of Vice President, Operations to oversee and accelerate market introduction of the Company’s products and services for Digitization and Tactical Products (“DTP”).
The DTP business unit comprises the bulk of the Company’s current products and services, including TASCS, ATAK integration, the GreyGhostTM micro missile against hostile drones, the laser defence system and the Phantom electronic decoy.
Appointments are part of KWESST’s expanded business plan
Ottawa, Ontario–(April 14, 2021) – KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) (“KWESST” or “the Company”) today announced that it has appointed Rick Bowes, CD, MA, MBA in the new position of Vice President, Operations to oversee and accelerate market introduction of the Company’s products and services for Digitization and Tactical Products (“DTP”). The DTP business unit comprises the bulk of the Company’s current products and services, including TASCS, ATAK integration, the GreyGhostTM micro missile against hostile drones, the laser defence system and the Phantom electronic decoy.
In conjunction, the Company also announced that Steve Archambault, who has been serving as part-time Chief Financial Officer since the Company’s listing in September 2020, will now assume this role on a full-time basis.
“With the expected closing of our recently announced $4 million over-subscribed brokered private placement, KWESST is positioned to execute on an expanded business plan,” said Jeff MacLeod, KWESST Founder, President and CEO. “The appointments announced today add bench strength for accelerated market introduction across our growing portfolio of products and services.”
“We are very pleased indeed to welcome Rick as VP Operations,” added David Luxton, Executive Chairman. “He brings a rare combination of senior defence industry experience and domain knowledge that is directly relevant to our key markets and programs. He also has proven business capture experience and long-standing relationships with major defence contractors. We are equally pleased that Steve Archambault has committed to the Company on a dedicated, full-time basis in the role of CFO.”
About Rick Bowes
Prior to his various senior roles with defence contractors such as General Dynamics Canada, DRS Technologies Canada (now Leonardo DRS), ATCO Frontec and ADGA Group Inc., Rick had a distinguished career as a senior officer in the Canadian Army, retiring in 2003 as a Lieutenant Colonel. He is a graduate of Royal Military College of Canada and served in various operational and staff roles in the Canadian military and on secondment to the British Army. As an armour officer, Rick served with various units such as Lord Strathcona’s Horse (Royal Canadians) and the Canadian Airborne Regiment Battle Group across Canada and in deployed operations in Bosnia-Herzegovina with the UN Protection Force and the NATO Stabilization Force (SFOR). Rick was also part of the planning team for Canada’s participation in the NATO Kosovo Force (KFOR) mission in 1999.
The Company stated that the terms of these appointments include a grant of 300,000 stock options to Rick Bowes, with each stock option being exercisable at a price equal to the closing price of the Company’s shares on the TSX Venture Exchange on April 16th, 2021 on or before April 13, 2026 and a grant of Restricted Share Units (“RSU”s) to Steve Archambault equal to $25,000 divided by the closing price of the Company’s shares on the TSX Venture Exchange on April 16th, 2021.
Posted by AGORACOM-JC
at 9:13 AM on Wednesday, April 14th, 2021
Announced the addition of perishable, refrigerated and frozen goods to its expanding repertoire of grocery items
Company will be enhancing its product offerings by adding high-quality fresh and frozen products by various plant-based brands including Beyond Meat, Impossible Foods, Miyokos, Follow Your Heart, Gardein, Tofurkey and Alpha Foods
This move will allow PlantX to significantly increase its product assortment at its one-stop-shop for everything plant-based e-commerce platform
VANCOUVER, BC , April 14, 2021 – PlantX Life Inc. (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) (” PlantX ” or the ” Company “) is pleased to announce the addition of perishable, refrigerated and frozen goods to its expanding repertoire of grocery items.
The Company will be enhancing its product offerings by adding high-quality fresh and frozen products by various plant-based brands including Beyond Meat, Impossible Foods, Miyokos, Follow Your Heart, Gardein, Tofurkey and Alpha Foods. This move will allow PlantX to significantly increase its product assortment at its one-stop-shop for everything plant-based e-commerce platform. The new items are now available to order in the ‘ Frozen ‘ and ‘ Refrigerated’ sections of the Company’s United States’ e-commerce platform . Frozen and refrigerated products will be available for shipping to Canadian customers later this year.
Temperature monitoring is crucial in ensuring the freshness of refrigerated and frozen items. A high number of touch points in the supply chain can affect temperature management due to the repeated loading and unloading or prolonged transfer time, which can therefore compromise product quality. To assist in bypassing these challenges, PlantX has partnered with a logistics provider that will deliver the new products from manufacturers to consumers’ homes in an efficient manner.
“Launching the new refrigerated and frozen product line is a natural and thrilling next step for PlantX,” said Julia Frank , PlantX CEO. “By adding such items, we are building on our efforts to create an online presence where customers can access a versatile range of high-quality products that meet their everyday needs.”
About PlantX Life Inc.
As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant-based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.
Posted by AGORACOM-JC
at 8:50 AM on Wednesday, April 14th, 2021
Announced that it will expand distribution of it Plant-Based Complete Nutrition for Toddlers into 159 Natural Grocers by Vitamin Cottage stores across 20 states as of May 2021
VANCOUVER, BC , April 14, 2021 – ELSE NUTRITION HOLDINGS INC.(TSXV: BABY.V) (OTCQX: BABYF) (FSE: 0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company , announces that it will expand distribution of it Plant-Based Complete Nutrition for Toddlers into 159 Natural Grocers by Vitamin Cottage stores across 20 states as of May 2021.
“Launching at Natural Grocers by Vitamin Cottage drives significant and strategic distribution for the brand. We are particularly excited by the alignment between this retailer and with our brand, both focusing on helping people through sustainable, organic nutrition solutions, said Hamutal Yitzhak , Else CEO and Co-Founder. “We are eager to bring real, organic and whole food-based, clean label solutions to families in this region,” she added.
About Natural Grocers by Vitamin Cottage
Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is one of the leading natural food grocers in the US, with 159 stores in 20 states west of the Mississippi river. Founded in 1955, Natural Grocers is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial colors, flavors, preservatives or sweeteners, or partially hydrogenated or hydrogenated oils. The Company sells only USDA certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers’ flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, safe, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers make informed health and nutrition choices.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Posted by AGORACOM-JC
at 8:44 AM on Wednesday, April 14th, 2021
Announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000
Valeo insiders participate for $2.6 million
MONTREAL , April 14, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000 (the “Offering”).
Each Debenture Unit will consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a “Debenture”) and 200 Class “A” share purchase warrants (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Class “A” Share of the Company (each, a “Share”) at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the “Closing Date”). The Debentures will mature at the latest 9 months after the closing and will bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears.
“We are appreciative of the continued support from insiders and investors close to the Company in this placement”, said Steve Saviuk , Valeo’s Chief Executive Officer. “This financing will strengthen our balance sheet at a time of three important product launches for Valeo, Enerzair® Breezhaler®, Atectura® Breezhaler® and Redesca™. Commercialized through two distinct sales forces, these products are key drivers to our growth over the coming years”.
The net proceeds of the Offering will be used for working capital and general corporate purposes.
Closing of the Private Placement is expected to occur on or about April 23, 2021 and is subject to regulatory approval including that of the CSE. The Company may pay finder’s fees on the non-insider portion of the Private Placement, in compliance with applicable securities laws. All securities issued in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.
The issuance of Convertible Debentures to the insiders will be considered related party transactions within the meaning of Multilateral Instrument 61-101 (“MI 61-101”). The Company intends to rely on the exemptions from the requirements of MI 61-101 in respect of any Insider Participation.
This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurology, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Posted by AGORACOM-JC
at 8:41 AM on Wednesday, April 14th, 2021
Forecourt operators to get access to real-time data from any point-of-sale through Loop’s IoT device
Announces a new Proof of Concept (PoC) with Suresite Group
The cooperation will see selected Suresite retail locations take advantage of Loop’s IoT Fobi device and Insights platform
LONDON and VANCOUVER, British Columbia, April 14, 2021 — Loop Insights (MTRX:TSXV; RACMF:OTCQB), a provider of contactless solutions and artificial intelligence for the brick and mortar space, announces a new Proof of Concept (PoC) with Suresite Group. The cooperation will see selected Suresite retail locations take advantage of Loop’s IoT Fobi device and Insights platform.
Loop Insights is growing its UK retail presence
According to KPMG , the UK’s forecourt or gas station convenience store sector generates approximately £4.5 billion in annual revenue. Loop’s latest agreement with Suresite represents its entry into the UK’s retail energy sectors, as part of wider business development efforts in the UK.
The changing trends of forecourt retail
Suresite ’s UK data of card payment transactions and spend show that in the last 12 months, there has been less demand for fuel with people unable to travel due to local and national lockdowns. Yet these travel restrictions have also led to a growth in non-fuel retail with customers choosing to carry out their grocery shopping locally at nearby fuel stations, looking to fulfil multiple purposes in a single trip with an increased appetite for cashless transactions. With the constantly changing trends and challenges brought by the pandemic, data insights are now more important for forecourt retail than ever.
Loop’s Fobi is an IoT device working with an AI-powered retail analytics platform that allows retailers unprecedented access to real-time transaction data from any point-of-sale (POS) – online, in-store, and across multiple properties.
During the PoC, Loop Insights will implement its Fobi device and Insights AI-powered analytics platform across numerous Suresite client locations. This will provide Suresite, and more importantly, its clients who operate leading fuel and convenience brands, with powerful, actionable data capabilities needed to deliver informed loyalty experience and drive operational efficiencies. Suresite’s forecourt client market currently includes major brands such as Harvest Energy, Gulf, Jet, and others.
“ Through services such as our real-time, data-driven fuel monitoring solution, Suresite understands that retailers need data to be delivered in real-time to be able to maximise revenue and wallet-share. For the retailer, it’s about understanding the shopping basket breakdown item by item, who made the purchase, and how. Or having the ability to see how a special promotion is performing in real time so adjustments can be made if needed. This is why Suresite has partnered with Loop Insights, to help our clients improve their business decisions based on real-time, actionable insights,” explains Eva Jones, Head of Product Development and Innovation at Suresite.
Loop Insights CEO Rob Anson stated: “Our latest Proof of Concept agreement with Suresite is additional proof that our Fobi device combined with our AI-powered Insights platform serves an immediate, data driven need in the convenience and fuel sectors. Recent announcements with Sobeys in grocery, and now Suresite in convenience and fuel – two of the largest retail sectors in the world – serve notice that Loop and its solutions are fit-for-purpose in today’s data-first world. We anticipate this PoC will be another massive success for both Loop and Suresite as we continue to demonstrate the power of Loop’s Insights platform no matter the industry or country.”
Suresite CEO Steve Hoban added: “We understand the power of insight to help our clients improve their offer, sales and profit. We are excited to partner with Loop and are looking forward to the results of our trials. Our aim is to continue to add value to our clients and be able to enrich our data to provide them with insights that help them grow.”
This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/LoopInsights .
About Suresite Group Established over 25 years ago, Suresite Group provides a range of business critical operational services for Fuel and Convenience Retailers. Suresite market leading Payment and data solutions, Wetstock management, Training and Health & Safety compliance help over 3,000 stores across the UK run businesses more effectively. Suresite Group customers and partners include Barclays, Worldpay, Timico, Feefo, American Express, Sponge, Greenergy, Cost Cutter, Jet, and others.
About Loop Insights Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”), automated marketing, venue tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.
This news release contains certain statements that constitute forward-looking statements or information, including statements regarding Loop’s business and technology; the ability of Loop to engage with industry participants to achieve its goals; the development of Loop’s technology; and the viability of Loop’s business model. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, competition from other industry participants, stock market volatility, and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated, or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity, or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 8:36 AM on Wednesday, April 14th, 2021
Announced that Kai Medical Laboratory has received an order for COVID-19 RT-PCR tests that is anticipated to be in excess of $CAD 750,000 from two new film and television productions.
VANCOUVER, BC / April 14, 2021 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce that Kai Medical Laboratory (“KAI”) has received an order for COVID-19 RT-PCR tests that is anticipated to be in excess of $CAD 750,000 from two new film and television productions.
5,000 TEST ORDER FOR FILM & TELEVISION PRODUCTIONS REPRESENTS REPEAT ORDER BASED ON CONSISTENT PERFORMANCE OF KAI MEDICAL LAB
In early October, shortly after the acquisition of KAI, Empower announced an agreement to process approximately 1,000 COVID-19 RT-PCR tests for a major film & TV production over a 30-day period, with the possibility of more business upon successful completion of the initial tests.
On November 16, 2020 KAI received a repeat and record COVID-19 testing order for approximately 9,000 units in excess of $CAD 1,000,000 over a four-month period.
Today’s announcement represents a repeat Purchase Order of approximately 5,000 units to be processed over just a two-month period. The total revenue from this order is anticipated to be in excess of $CAN 750,000.
“Our team at KAI continues to deliver the type of performance to Tier-1 clients that is worthy of significant repeat business that serves as unequivocal validation of our capabilities,” said Steven McAuley, Chairman & CEO of Empower. “To this end, the magnitude of KAI’s growth and success cannot be overstated as it continues to focus on very active business development and product development, setting a path toward significant North American growth in the midst of tripling its size. KAI is well on its way to becoming a national brand supported by our strong working capital position and a team dedicated to performance.”
As of September 1st, KAI has already processed tests for multiple different film and television productions in key US markets including Los Angeles, Atlanta, New York, Dallas, earning the highest confidence of the industry.
KAI MEDICAL LABORATORY NOW EXPANDING TO TRIPLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED RAPID TEST GROWTH
KAI continues to progress on the design and build out of the laboratory expansion to prepare to meet upcoming demand in a number of areas. First, the continued processing of RT-PCR tests for film & television productions, commercial accounts and enterprise level clients. Second, the full e-commerce impact of KaiTests.com and the national direct-to-consumer marketing programs for KAI Saliva, an FDA, EUA authorized and Health Canada approved at-home Saliva COVID-19 RT-PCR Test. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into Canada and USA, or arriving in other countries that have similar executive travel orders.
Finally, KAI Labs continues the development of new direct-to-consumer test protocols that will expand the product offers on Kaitests.com throughout 2021 and beyond.
McAuley added “With each passing month Empower gains more strength and velocity in every aspect of our business from KAI Lab in Dallas to our rapidly expanding clinic operations in Canada and our direct-to-consumer products such as KAI Saliva. All of which are amply funded well into the future with our strongest balance sheet ever thanks to the receipt of more than $12,000,000 in warrant conversions as of last month. We are on a path, a trajectory towards building a great health and wellness company across North America, and I look forward to providing our shareholders with further specifics.”
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
Tags: covid19, Covid19 testing, CSE, Diagnos Inc, investments, small cap Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab Receives Order for Up To 5,000 Covid-19 Tests from Two Film & Television Productions in Excess Of $750,000 $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca
